Alejandra Palacios, president of the Federal Commission of Economic Competition (COFECE) of Mexico, declared that a lack of competition and abuse of market power by certain pharmaceutical companies in collusion with public authorities has meant that “Mexican households pay an average of 98 percent more than they would pay without surcharges ” when buying medicines.
Featured News
Beumer Challenges EU Decision on Vanderlande-Siemens Merger Review
Jul 26, 2026 by
CPI
China Fines Trip.com US$765 Million in Major Antitrust Enforcement Action
Jul 26, 2026 by
CPI
House Judiciary Panel Launches Antitrust Inquiry Into Compass and MRED
Jul 26, 2026 by
CPI
Paramount Delays Warner Bros. Discovery Merger Until Antitrust Case Moves Forward
Jul 26, 2026 by
CPI
Judge Pushes Elite College Financial Aid Antitrust Trial Toward Thanksgiving Finish
Jul 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes